Cytodyn Inc (CYDY)

[drfreak]

Agreed.

24% is a big number when you compare it to some of the benefits adjuvant cancer therapies provide - http://www.lifemath.net/cancer/breastcancer/therapy/

While Leronlimab and systemic therapies for breast and other cancers both improve survival, there is no comparison with regards to their toxicities.

The 2005 study in the NEJM for adjuvant herceptin had a similar survival benefit (33% reduction in the risk of death) with a much larger sample size (n=2000+).

So to go back to the original question, yes every year thousands of women who are HER2/neu +ve are offered a treatment which has a 33% benefit. Unlike Leronlimab, Herceptin unfortunately has more reported side effects ( https://www.webmd.com/drugs/2/drug-16621/herceptin-intravenous/details/list-sideeffects ).